Altered methylation of imprinted genes in neuroblastoma: implications for prognostic refinement.
Copy number alterations
DNA methylation
Genomic imprinting
Neuroblastoma
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
31 Aug 2024
31 Aug 2024
Historique:
received:
17
06
2024
accepted:
22
08
2024
medline:
1
9
2024
pubmed:
1
9
2024
entrez:
31
8
2024
Statut:
epublish
Résumé
Neuroblastoma (NB) is a complex disease, and the current understanding of NB biology is limited. Deregulation in genomic imprinting is a common event in malignancy. Since imprinted genes play crucial roles in early fetal growth and development, their role in NB pathogenesis could be suggested. We examined alterations in DNA methylation patterns of 369 NB tumours at 49 imprinted differentially methylated regions (DMRs) and assessed its association with overall survival probabilities and selected clinical and genomic features of the tumours. In addition, an integrated analysis of DNA methylation and allele-specific copy number alterations (CNAs) was performed, to understand the correlation between the two molecular events. Several imprinted regions with aberrant methylation patterns in NB were identified. Regions that underwent loss of methylation in > 30% of NB samples were DMRs annotated to the genes NDN, SNRPN, IGF2, MAGEL2 and HTR5A and regions with gain of methylation were NNAT, RB1 and GPR1. Methylation alterations at six of the 49 imprinted DMRs were statistically significantly associated with reduced overall survival: MIR886, RB1, NNAT/BLCAP, MAGEL2, MKRN3 and INPP5F. RB1, NNAT/BLCAP and MKRN3 were further able to stratify low-risk NB tumours i.e. tumours that lacked MYCN amplification and 11q deletion into risk groups. Methylation alterations at NNAT/BLCAP, MAGEL2 and MIR886 predicted risk independently of MYCN amplification or 11q deletion and age at diagnosis. Investigation of the allele-specific CNAs demonstrated that the imprinted regions that displayed most alterations in NB tumours harbor true epigenetic changes and are not result of the underlying CNAs. Aberrant methylation in imprinted regions is frequently occurring in NB tumours and several of these regions have independent prognostic value. Thus, these could serve as potentially important clinical epigenetic markers to identify individuals with adverse prognosis. Incorporation of methylation status of these regions together with the established risk predictors may further refine the prognostication of NB patients.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroblastoma (NB) is a complex disease, and the current understanding of NB biology is limited. Deregulation in genomic imprinting is a common event in malignancy. Since imprinted genes play crucial roles in early fetal growth and development, their role in NB pathogenesis could be suggested.
METHODS
METHODS
We examined alterations in DNA methylation patterns of 369 NB tumours at 49 imprinted differentially methylated regions (DMRs) and assessed its association with overall survival probabilities and selected clinical and genomic features of the tumours. In addition, an integrated analysis of DNA methylation and allele-specific copy number alterations (CNAs) was performed, to understand the correlation between the two molecular events.
RESULTS
RESULTS
Several imprinted regions with aberrant methylation patterns in NB were identified. Regions that underwent loss of methylation in > 30% of NB samples were DMRs annotated to the genes NDN, SNRPN, IGF2, MAGEL2 and HTR5A and regions with gain of methylation were NNAT, RB1 and GPR1. Methylation alterations at six of the 49 imprinted DMRs were statistically significantly associated with reduced overall survival: MIR886, RB1, NNAT/BLCAP, MAGEL2, MKRN3 and INPP5F. RB1, NNAT/BLCAP and MKRN3 were further able to stratify low-risk NB tumours i.e. tumours that lacked MYCN amplification and 11q deletion into risk groups. Methylation alterations at NNAT/BLCAP, MAGEL2 and MIR886 predicted risk independently of MYCN amplification or 11q deletion and age at diagnosis. Investigation of the allele-specific CNAs demonstrated that the imprinted regions that displayed most alterations in NB tumours harbor true epigenetic changes and are not result of the underlying CNAs.
CONCLUSIONS
CONCLUSIONS
Aberrant methylation in imprinted regions is frequently occurring in NB tumours and several of these regions have independent prognostic value. Thus, these could serve as potentially important clinical epigenetic markers to identify individuals with adverse prognosis. Incorporation of methylation status of these regions together with the established risk predictors may further refine the prognostication of NB patients.
Identifiants
pubmed: 39217334
doi: 10.1186/s12967-024-05634-5
pii: 10.1186/s12967-024-05634-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
808Informations de copyright
© 2024. The Author(s).
Références
Newman EA, Abdessalam S, Aldrink JH, Austin M, Heaton TE, Bruny J, et al. Update on neuroblastoma. J Pediatr Surg. 2019;54(3):383–9.
pubmed: 30305231
doi: 10.1016/j.jpedsurg.2018.09.004
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–17.
pubmed: 26304901
pmcid: 4567703
doi: 10.1200/JCO.2014.59.4648
London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123(24):4914–23.
pubmed: 28885700
doi: 10.1002/cncr.30934
Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416(2):153–9.
pubmed: 18990089
doi: 10.1042/BJ20081834
Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, De Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455(7215):967–70.
pubmed: 18923523
doi: 10.1038/nature07398
Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–5.
pubmed: 18724359
pmcid: 2672043
doi: 10.1038/nature07261
Rosswog C, Fassunke J, Ernst A, Schömig-Markiefka B, Merkelbach-Bruse S, Bartenhagen C, et al. Genomic ALK alterations in primary and relapsed neuroblastoma. Br J Cancer. 2023;128(8):1559–71.
pubmed: 36807339
pmcid: 10070426
doi: 10.1038/s41416-023-02208-y
Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, et al. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol. 2014;32(25):2727–34.
pubmed: 25071110
doi: 10.1200/JCO.2013.54.0674
Padovan-Merhar OM, Raman P, Ostrovnaya I, Kalletla K, Rubnitz KR, Sanford EM, et al. Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLoS Genet. 2016;12(12): e1006501.
pubmed: 27997549
pmcid: 5172533
doi: 10.1371/journal.pgen.1006501
Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010;107(9):4323–8.
pubmed: 20145112
pmcid: 2840092
doi: 10.1073/pnas.0910684107
Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27(7):1026–33.
pubmed: 19171713
doi: 10.1200/JCO.2008.16.0630
Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015;47(8):864–71.
pubmed: 26121087
pmcid: 4775079
doi: 10.1038/ng.3333
Aktas T, Kızmazoglu D, Aktas S, Erol A, Serinan E, Gokbayrak O, et al. Unraveling the mystery: next generation sequencing sheds light on neuroblastoma pathogenesis and targeted therapies. Front Biosci (Landmark Ed). 2023;28(8):171.
pubmed: 37664946
doi: 10.31083/j.fbl2808171
George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975–8.
pubmed: 18923525
pmcid: 2587486
doi: 10.1038/nature07397
Pastorino F, Capasso M, Brignole C, Lasorsa VA, Bensa V, Perri P, et al. Therapeutic targeting of ALK in neuroblastoma: experience of Italian precision medicine in pediatric oncology. Cancers (Basel). 2023;15(3):560.
pubmed: 36765519
pmcid: 9913103
doi: 10.3390/cancers15030560
Kameneva P, Artemov AV, Kastriti ME, Faure L, Olsen TK, Otte J, et al. Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin. Nat Genet. 2021;53(5):694–706.
pubmed: 33833454
pmcid: 7610777
doi: 10.1038/s41588-021-00818-x
Körber V, Stainczyk SA, Kurilov R, Henrich K-O, Hero B, Brors B, et al. Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome. Nat Genet. 2023;55(4):619–30.
pubmed: 36973454
pmcid: 10101850
doi: 10.1038/s41588-023-01332-y
Jansky S, Sharma AK, Körber V, Quintero A, Toprak UH, Wecht EM, et al. Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma. Nat Genet. 2021;53(5):683–93.
pubmed: 33767450
doi: 10.1038/s41588-021-00806-1
Kildisiute G, Kholosy WM, Young MD, Roberts K, Elmentaite R, van Hooff SR, et al. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. Sci Adv. 2021;7(6):eabd3311.
pubmed: 33547074
pmcid: 7864567
doi: 10.1126/sciadv.abd3311
Ferguson-Smith AC. Genomic imprinting: the emergence of an epigenetic paradigm. Nat Rev Genet. 2011;12(8):565–75.
pubmed: 21765458
doi: 10.1038/nrg3032
Horsthemke B. In brief: genomic imprinting and imprinting diseases. J Pathol. 2014;232(5):485–7.
pubmed: 24395592
doi: 10.1002/path.4326
Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, et al. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood. 1998;91(9):3144–7.
pubmed: 9558368
doi: 10.1182/blood.V91.9.3144
Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med. 1998;4(11):1276–80.
pubmed: 9809551
doi: 10.1038/3260
Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui H, Casson AG. Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues. Carcinogenesis. 2009;30(12):2117–22.
pubmed: 19843644
doi: 10.1093/carcin/bgp254
Zhou J, Cheng T, Li X, Hu J, Li E, Ding M, et al. Epigenetic imprinting alterations as effective diagnostic biomarkers for early-stage lung cancer and small pulmonary nodules. Clin Epigenetics. 2021;13(1):220.
pubmed: 34906185
pmcid: 8672623
doi: 10.1186/s13148-021-01203-5
Henrich K-O, Bender S, Saadati M, Dreidax D, Gartlgruber M, Shao C, et al. Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional deregulation in unfavorable neuroblastomas. Can Res. 2016;76(18):5523–37.
doi: 10.1158/0008-5472.CAN-15-2507
Olsson M, Beck S, Kogner P, Martinsson T, Carén H. Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors. Epigenetics. 2016;11(1):74–84.
pubmed: 26786290
pmcid: 4846113
doi: 10.1080/15592294.2016.1138195
Daenekas B, Pérez E, Boniolo F, Stefan S, Benfatto S, Sill M, et al. Conumee 2.0: enhanced copy-number variation analysis from DNA methylation arrays for humans and mice. Bioinformatics. 2024;40(2).
Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics. 2017;33(24):3982–4.
pubmed: 28961746
pmcid: 5860089
doi: 10.1093/bioinformatics/btx513
Hernandez Mora JR, Tayama C, Sánchez-Delgado M, Monteagudo-Sánchez A, Hata K, Ogata T, et al. Characterization of parent-of-origin methylation using the Illumina Infinium MethylationEPIC array platform. Epigenomics. 2018;10(7):941–54.
pubmed: 29962238
doi: 10.2217/epi-2017-0172
Martin-Trujillo A, Vidal E, Monteagudo-Sánchez A, Sanchez-Delgado M, Moran S, Hernandez Mora JR, et al. Copy number rather than epigenetic alterations are the major dictator of imprinted methylation in tumors. Nat Commun. 2017;8(1):467.
pubmed: 28883545
pmcid: 5589900
doi: 10.1038/s41467-017-00639-9
Van Loo P, Nilsen G, Nordgard SH, Vollan HK, Børresen-Dale AL, Kristensen VN, et al. Analyzing cancer samples with SNP arrays. Methods Mol Biol. 2012;802:57–72.
pubmed: 22130873
doi: 10.1007/978-1-61779-400-1_4
Borgan Ø. Modeling Survival Data: Extending the Cox Model. Terry M. Therneau and Patricia M. Grambsch, Springer-Verlag, New York, 2000. No. of pages: xiii + 350. Price: $69.95. ISBN 0-387-98784-3. Statistics in Medicine. 2001;20(13):2053–4.
Capper D, Jones DT, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469–74.
pubmed: 29539639
pmcid: 6093218
doi: 10.1038/nature26000
Schepke E, Löfgren M, Pietsch T, Olsson Bontell T, Kling T, Wenger A, et al. DNA methylation profiling improves routine diagnosis of paediatric central nervous system tumours: a prospective population-based study. Neuropathol Appl Neurobiol. 2022;48(6): e12838.
pubmed: 35892159
pmcid: 9543790
doi: 10.1111/nan.12838
Ferreyra Vega S, Olsson Bontell T, Corell A, Smits A, Jakola AS, Carén H. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clin Epigenetics. 2021;13(1):102.
pubmed: 33941250
pmcid: 8091784
doi: 10.1186/s13148-021-01085-7
Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018;362(6419):1165–70.
pubmed: 30523111
pmcid: 7875194
doi: 10.1126/science.aat6768
Higashi M, Tajiri T, Kinoshita Y, Tatsuta K, Souzaki R, Maehara Y, et al. High expressions of neuronatin isoforms in favorable neuroblastoma. J Pediatr Hematol Oncol. 2007;29(8):551–6.
pubmed: 17762496
doi: 10.1097/MPH.0b013e3181256b7b
Yáñez Y, Grau E, Rodríguez-Cortez VC, Hervás D, Vidal E, Noguera R, et al. Two independent epigenetic biomarkers predict survival in neuroblastoma. Clin Epigenetics. 2015;7(1):16.
pubmed: 25767620
pmcid: 4357365
doi: 10.1186/s13148-015-0054-8
Ribarska T, Goering W, Droop J, Bastian KM, Ingenwerth M, Schulz WA. Deregulation of an imprinted gene network in prostate cancer. Epigenetics. 2014;9(5):704–17.
pubmed: 24513574
pmcid: 4063830
doi: 10.4161/epi.28006
De Faveri LE, Hurst CD, Platt FM, Taylor CF, Roulson JA, Sanchez-Carbayo M, et al. Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer. Br J Cancer. 2013;108(6):1368–77.
pubmed: 23549060
pmcid: 3619261
doi: 10.1038/bjc.2013.104
Hayashi Y, Matsuyama K, Takagi K, Sugiura H, Yoshikawa K. Arrest of cell growth by necdin, a nuclear protein expressed in postmitotic neurons. Biochem Biophys Res Commun. 1995;213(1):317–24.
pubmed: 7639751
doi: 10.1006/bbrc.1995.2132
Chapman EJ, Kelly G, Knowles MA. Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res. 2008;6(7):1154–68.
pubmed: 18644980
pmcid: 3437422
doi: 10.1158/1541-7786.MCR-07-2168
Taniura H, Matsumoto K, Yoshikawa K. Physical and functional interactions of neuronal growth suppressor necdin with p53. J Biol Chem. 1999;274(23):16242–8.
pubmed: 10347180
doi: 10.1074/jbc.274.23.16242
Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009;4(1):37–48.
pubmed: 19128791
pmcid: 2839936
doi: 10.1016/j.stem.2008.11.006
Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822–35.
pubmed: 27132212
doi: 10.1016/S1470-2045(16)00099-1
Yang B, O’Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Can Res. 2007;67(20):9954–62.
doi: 10.1158/0008-5472.CAN-07-1478
Zeng Z-L, Wu W-J, Yang J, Tang Z-J, Chen D-L, Qiu M-Z, et al. Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma. J Transl Med. 2012;10:1–9.
doi: 10.1186/1479-5876-10-181
Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL, et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011;13(2):165–75.
pubmed: 21177782
doi: 10.1093/neuonc/noq179
Liu X-L, Zhao D, Sun D-P, Wang Y, Li Y, Qiu F-Q, et al. Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87. J Exp Clin Cancer Res. 2012;31:1–10.
doi: 10.1186/1756-9966-31-8
Plasterer C, Semenikhina M, Tsaih SW, Flister MJ, Palygin O. NNAT is a novel mediator of oxidative stress that suppresses ER + breast cancer. Mol Med. 2023;29(1):87.
pubmed: 37400769
pmcid: 10318825
doi: 10.1186/s10020-023-00673-y
Novotny NM, Grosfeld JL, Turner KE, Rescorla FJ, Pu X, Klaunig JE, et al. Oxidative status in neuroblastoma: a source of stress? J Pediatr Surg. 2008;43(2):330–4.
pubmed: 18280284
pmcid: 2804860
doi: 10.1016/j.jpedsurg.2007.10.040
Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Can Res. 2013;73(11):3326–35.
doi: 10.1158/0008-5472.CAN-12-3055
Lee H-S, Lee K, Jang H-J, Lee GK, Park J-L, Kim S-Y, et al. Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis. Oncotarget. 2014;5(11):3472.
pubmed: 25004084
pmcid: 4116496
doi: 10.18632/oncotarget.1927
Treppendahl MB, Qiu X, Søgaard A, Yang X, Nandrup-Bus C, Hother C, et al. Allelic methylation levels of the noncoding VTRNA2–1 located on chromosome 5q31. 1 predict outcome in AML. Blood J Am Soc Hematol. 2012;119(1):206–16.
Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013;3(10): a014415.
pubmed: 24086065
pmcid: 3784814
doi: 10.1101/cshperspect.a014415
Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999;18(35):4948–57.
pubmed: 10490829
doi: 10.1038/sj.onc.1202887
Plantaz D, Vandesompele J, Van Roy N, Łastowska M, Bown N, Combaret V, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer. 2001;91(5):680–6.
pubmed: 11267980
doi: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R
Bildik G, Liang X, Sutton MN, Bast RC Jr, Lu Z. DIRAS3: an imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy, and tumor dormancy. Mol Cancer Ther. 2022;21(1):25–37.
pubmed: 34667114
doi: 10.1158/1535-7163.MCT-21-0331
Dai J, Chen Q, Li G, Chen M, Sun H, Yan M. DIRAS3, GPR171 and RAC2 were identified as the key molecular patterns associated with brain metastasis of breast cancer. Front Oncol. 2022;12: 965136.
pubmed: 36212434
pmcid: 9532569
doi: 10.3389/fonc.2022.965136
Kumar JD, Aolymat I, Tiszlavicz L, Reisz Z, Garalla HM, Beynon R, et al. Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2. Oncotarget. 2019;10(2):98.
pubmed: 30719206
pmcid: 6349446
doi: 10.18632/oncotarget.26414
Huang C, Dai XY, Cai JX, Chen J, Wang BB, Zhu W, et al. A screened GPR1 peptide exerts antitumor effects on triple-negative breast cancer. Mol Ther Oncolytics. 2020;18:602–12.
pubmed: 33005727
pmcid: 7508919
doi: 10.1016/j.omto.2020.08.013
Zhao R, Ge Y, Gong Y, Li B, Xiao B, Zuo S. NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway. Aging (Albany NY). 2022;14(22):9000–19.
pubmed: 36374212
doi: 10.18632/aging.204377
Zhang Z, He G, Lv Y, Liu Y, Niu Z, Feng Q, et al. HERC3 regulates epithelial-mesenchymal transition by directly ubiquitination degradation EIF5A2 and inhibits metastasis of colorectal cancer. Cell Death Dis. 2022;13(1):74.
pubmed: 35064108
pmcid: 8782983
doi: 10.1038/s41419-022-04511-7
Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, et al. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA. 2011;17(6):1076–89.
pubmed: 21518807
pmcid: 3096040
doi: 10.1261/rna.2701111
Pan B, Yu J, Liu X. Upregulation of miR-886 indicates poor prognosis and promotes tumour progression of prostate cancer. Andrologia. 2022;54(1): e14296.
pubmed: 34787343
doi: 10.1111/and.14296
Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 2013;73(11):3326–35.
pubmed: 23592755
doi: 10.1158/0008-5472.CAN-12-3055
Temple IK, Mackay DJG. Diabetes Mellitus, 6q24-Related Transient Neonatal. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews(®). Seattle: University of Washington.
Copyright © 1993–2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993.
Chen Y, Tang M, Xiong J, Gao Q, Cao W, Huang J. GRB10 is a novel oncogene associated with cell proliferation and prognosis in glioma. Cancer Cell Int. 2022;22(1):223.
pubmed: 35790975
pmcid: 9254544
doi: 10.1186/s12935-022-02636-5
Okabe H, Satoh S, Furukawa Y, Kato T, Hasegawa S, Nakajima Y, et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Can Res. 2003;63(12):3043–8.
Peng Y-P, Zhu Y, Yin L-D, Zhang J-J, Wei J-S, Liu X, et al. PEG10 overexpression induced by E2F–1 promotes cell proliferation, migration, and invasion in pancreatic cancer. J Exp Clin Cancer Res. 2017;36:1–12.
doi: 10.1186/s13046-017-0500-x
Li C-M, Margolin AA, Salas M, Memeo L, Mansukhani M, Hibshoosh H, et al. PEG10 is a c-MYC target gene in cancer cells. Can Res. 2006;66(2):665–72.
doi: 10.1158/0008-5472.CAN-05-1553
Liu D-C, Yang Z-L, Jiang S. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res. 2011;17:859–66.
pubmed: 21455631
doi: 10.1007/s12253-011-9394-7
Gao S, Lu X, Ma J, Zhou Q, Tang R, Fu Z, et al. Comprehensive analysis of lncRNA and miRNA regulatory network reveals potential prognostic non-coding RNA involved in breast cancer progression. Front Genet. 2021;12: 621809.
pubmed: 34220926
pmcid: 8253500
doi: 10.3389/fgene.2021.621809
Xu WW, Liao L, Dai W, Zheng CC, Tan XP, He Y, et al. Genome-wide CRISPR/Cas9 screening identifies a targetable MEST-PURA interaction in cancer metastasis. EBioMedicine. 2023;92: 104587.
pubmed: 37149929
pmcid: 10192437
doi: 10.1016/j.ebiom.2023.104587
Zhao R, Wei W, Zhen L. WGCNA-based identification of potential targets and pathways in response to treatment in locally advanced breast cancer patients. Open Med (Wars). 2023;18(1):20230651.
pubmed: 36896338
doi: 10.1515/med-2023-0651
Boot A, Oosting J, Doorn S, Ouahoud S, Ventayol Garcia M, Ruano D, et al. Allelic switching of DLX5, GRB10, and SVOPL during colorectal cancer tumorigenesis. Int J Genomics. 2019;2019:1287671.
pubmed: 31093489
pmcid: 6481143
doi: 10.1155/2019/1287671
Lu Q, Ding Y, Li Y, Lu Q. 5-HT receptor agonist Valerenic Acid enhances the innate immunity signal and suppresses glioblastoma cell growth and invasion. Int J Biol Sci. 2020;16(12):2104–15.
pubmed: 32549758
pmcid: 7294948
doi: 10.7150/ijbs.44906
Zhang X, Cai J, Zheng Z, Polin L, Lin Z, Dandekar A, et al. A novel ER–microtubule-binding protein, ERLIN2, stabilizes Cyclin B1 and regulates cell cycle progression. Cell Discovery. 2015;1(1):15024.
pubmed: 27462423
pmcid: 4860859
doi: 10.1038/celldisc.2015.24
Zhang Y, Liu S, Wang H, Yang W, Li F, Yang F, et al. Elevated NIBP/TRAPPC9 mediates tumorigenesis of cancer cells through NFκB signaling. Oncotarget. 2015;6(8):6160–78.
pubmed: 25704885
pmcid: 4467429
doi: 10.18632/oncotarget.3349
Kim HS, Li A, Ahn S, Song H, Zhang W. Inositol Polyphosphate-5-phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity. Sci Rep. 2014;4(1):7330.
pubmed: 25476455
pmcid: 4256660
doi: 10.1038/srep07330
Zhang K, Luo Z, Zhang Y, Zhang L, Wu L, Liu L, et al. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer. Cancer Biomark. 2016;17(2):187–94.
pubmed: 27540977
doi: 10.3233/CBM-160630
Yang W, Ning N, Jin X. The lncRNA H19 promotes cell proliferation by competitively binding to miR-200a and derepressing β-catenin expression in colorectal cancer. BioMed Res Int. 2017;2017:1.
Zhao Y, Feng C, Li Y, Ma Y, Cai R. LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR-200a function. Mol Cell Biochem. 2019;460:1–8.
pubmed: 31187349
doi: 10.1007/s11010-019-03564-1
Zhang W, Zhou K, Zhang X, Wu C, Deng D, Yao Z. Roles of the H19/microRNA‑675 axis in the proliferation and epithelial‑mesenchymal transition of human cutaneous squamous cell carcinoma cells. Oncol Rep. 2021;45(4).
Gao S, Lin Z, Li C, Wang Y, Yang L, Zou B, et al. lncINS-IGF2 promotes cell proliferation and migration by promoting G1/S transition in lung cancer. Technol Cancer Res Treat. 2019;18:1533033818823029.
pubmed: 30803359
pmcid: 6374000
doi: 10.1177/1533033818823029
Gronbaek H, Flyvbjerg A, Mellemkjaer L, Tjonneland A, Christensen J, Sorensen H, et al. Serum insulin-like growth factors, insulin-like growth factor binding proteins and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomark Prev. 2004;13:1759–64.
doi: 10.1158/1055-9965.1759.13.11
Guerra F, Eijan A, Puricelli L, Alonso D, Bal de Kier Joffe E, Kornblihgtt A, et al. Varying patterns of expression of insulin-like growth factors-I and-II and their receptors in murine mammary adenocarcinoma of different metastasizing ability. Int J Cancer. 1996;65:812–20.
pubmed: 8631597
doi: 10.1002/(SICI)1097-0215(19960315)65:6<812::AID-IJC18>3.0.CO;2-5
Hakam A, Yeatman T, Lu L, Mora L, Marcet G, Nicosia S, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1999;30:1128–33.
pubmed: 10534157
doi: 10.1016/S0046-8177(99)90027-8
Kim K, Bae S, Lee O, Bae M, Lee M, Park B. Insulin-like growth factor-II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Can Res. 1998;58:348–51.
Chen Q, Sun T, Wang F, Gong B, Xie W, Ma M, et al. Long noncoding RNA IGF2AS is acting as an epigenetic tumor suppressor in human prostate cancer. Urology. 2019;124:310.e1-e8.
pubmed: 30423304
doi: 10.1016/j.urology.2018.11.002
Liu G, Shi L, Wang B, Wu Z, Zhao H, Zhao T, et al. Role of oncogenic long noncoding RNA KCNQ1OT1 in colon cancer. Oncol Res. 2024;32(3):585–96.
pubmed: 38361755
pmcid: 10865742
doi: 10.32604/or.2023.029349
De Rosa P, Severi F, Zadran SK, Russo M, Aloisi S, Rigamonti A, et al. MYCN amplification, along with wild-type RB1 expression, enhances CDK4/6 inhibitors’ efficacy in neuroblastoma cells. Int J Mol Sci. 2023;24(6):5408.
pubmed: 36982482
pmcid: 10049239
doi: 10.3390/ijms24065408
Xie B, Tan G, Ren J, Lu W, Pervaz S, Ren X, et al. RB1 is an immune-related prognostic biomarker for ovarian cancer. Front Oncol. 2022;12: 830908.
pubmed: 35299734
pmcid: 8920998
doi: 10.3389/fonc.2022.830908
Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, et al. RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Sci Adv. 2022;8(7):eabl9794.
pubmed: 35179959
pmcid: 8856618
doi: 10.1126/sciadv.abl9794
Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784–93.
pubmed: 31228622
pmcid: 6764905
doi: 10.1016/j.jtho.2019.06.002
Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011;10(10):1563–70.
pubmed: 21502814
doi: 10.4161/cc.10.10.15703
Xu J, Wang X, Zhu C, Wang K. A review of current evidence about lncRNA MEG3: a tumor suppressor in multiple cancers. Front Cell Dev Biol. 2022;10: 997633.
pubmed: 36544907
pmcid: 9760833
doi: 10.3389/fcell.2022.997633
Du Z, Tan F, Chen J, Wang B, Liu Y, Zhao F, et al. MEG8: an indispensable long non-coding RNA in multiple cancers. Curr Pharm Des. 2022;28(20):1688–94.
pubmed: 35578848
doi: 10.2174/1381612828666220516090245
Li K, Zheng X, Tang H, Zang YS, Zeng C, Liu X, et al. E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer. J Exp Med. 2021;218(8).
Arora M, Kumari S, Singh J, Chopra A, Chauhan SS. Downregulation of brain enriched type 2 MAGEs is associated with immune infiltration and poor prognosis in glioma. Front Oncol. 2020;10: 573378.
pubmed: 33425727
pmcid: 7787151
doi: 10.3389/fonc.2020.573378
Chapman EJ, Knowles MA. Necdin: a multi functional protein with potential tumor suppressor role? Mol Carcinogenesis. 2009;48(11):975–81.
doi: 10.1002/mc.20567
Ji M, Ren L, Lv Y, Lao X, Feng Q, Tang W, et al. Small nuclear ribonucleoprotein polypeptide N accelerates malignant progression and poor prognosis in colorectal cancer transcriptionally regulated by E2F8. Front Oncol. 2020;10: 561287.
pubmed: 33224876
pmcid: 7669248
doi: 10.3389/fonc.2020.561287
Saville B, Poukka H, Wormke M, Janne OA, Palvimo JJ, Stoner M, et al. Cooperative coactivation of estrogen receptor alpha in ZR-75 human breast cancer cells by SNURF and TATA-binding protein. J Biol Chem. 2002;277(4):2485–97.
pubmed: 11696545
doi: 10.1074/jbc.M109021200
Alfaro-Arnedo E, López IP, Piñeiro-Hermida S, Canalejo M, Gotera C, Sola JJ, et al. IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression. Oncogene. 2022;41(28):3625–39.
pubmed: 35688943
pmcid: 9184253
doi: 10.1038/s41388-022-02376-w
Yu J, Liang QY, Wang J, Cheng Y, Wang S, Poon TCW, et al. Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene. 2013;32(3):307–17.
pubmed: 22370639
doi: 10.1038/onc.2012.54
Vedeld HM, Nesbakken A, Lothe RA, Lind GE. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin Epigenetics. 2018;10:70.
pubmed: 29854011
pmcid: 5975481
doi: 10.1186/s13148-018-0503-2
Zhang G, Lv X, Yang Q, Liu H. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma. BMC Cancer. 2022;22(1):888.
pubmed: 35964022
pmcid: 9375928
doi: 10.1186/s12885-022-09987-2
Han F, Hu M, Zhang L, Fan X, Wang J, Lou Z, et al. A-to-I RNA editing of BLCAP promotes cell proliferation by losing the inhibitory of Rb1 in colorectal cancer. Exp Cell Res. 2022;417(2): 113209.
pubmed: 35605649
doi: 10.1016/j.yexcr.2022.113209
Gromova I, Svensson S, Gromov P, Moreira JM. Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer. PLoS ONE. 2017;12(11): e0188827.
pubmed: 29190807
pmcid: 5708675
doi: 10.1371/journal.pone.0188827
Xiong H, Chen G, Fang K, Gu W, Qiu F. Neuronatin promotes the progression of non-small cell lung cancer by activating the NF-κB signaling. Curr Cancer Drug Targets. 2024.
Xu DS, Yang C, Proescholdt M, Bründl E, Brawanski A, Fang X, et al. Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival. PLoS ONE. 2012;7(5): e37811.
pubmed: 22624064
pmcid: 3356299
doi: 10.1371/journal.pone.0037811
Yokota N, Mainprize TG, Taylor MD, Kohata T, Loreto M, Ueda S, et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene. 2004;23(19):3444–53.
pubmed: 15064731
doi: 10.1038/sj.onc.1207475
Gurvich N, Perna F, Farina A, Voza F, Menendez S, Hurwitz J, et al. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci U S A. 2010;107(52):22552–7.
pubmed: 21149733
pmcid: 3012470
doi: 10.1073/pnas.1017092108
Ding H, Zhang X, Su Y, Jia C, Dai C. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation. Cell Mol Biol Lett. 2020;25(1):8.
pubmed: 32123532
pmcid: 7038622
doi: 10.1186/s11658-020-00204-1
Koedoot E, van Steijn E, Vermeer M, González-Prieto R, Vertegaal ACO, Martens JWM, et al. Splicing factors control triple-negative breast cancer cell mitosis through SUN2 interaction and sororin intron retention. J Exp Clin Cancer Res. 2021;40(1):82.
pubmed: 33648524
pmcid: 7919097
doi: 10.1186/s13046-021-01863-4